1 / 28

IV CURSO PARA RESIDENTES DE LA AEEH DIAGNÓSTICO Y TRATAMIENTO DE LAS ENFERMEDADES HEPÁTICAS

SINDROME HEPATORRENAL. IV CURSO PARA RESIDENTES DE LA AEEH DIAGNÓSTICO Y TRATAMIENTO DE LAS ENFERMEDADES HEPÁTICAS Barcelona, 18-19 de Octubre de 2013. ASCITIS Y SINDROME HEPATORRENAL. Pere Ginès. Servei d’Hepatologia Hospital Clínic Universitat de Barcelona.

bmurillo
Download Presentation

IV CURSO PARA RESIDENTES DE LA AEEH DIAGNÓSTICO Y TRATAMIENTO DE LAS ENFERMEDADES HEPÁTICAS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SINDROME HEPATORRENAL IV CURSO PARA RESIDENTES DE LA AEEH DIAGNÓSTICO Y TRATAMIENTO DE LAS ENFERMEDADES HEPÁTICAS Barcelona, 18-19 de Octubre de 2013 ASCITIS Y SINDROME HEPATORRENAL Pere Ginès Servei d’Hepatologia Hospital Clínic Universitat de Barcelona

  2. ASCITES Pathogenesis and established therapies CIRRHOSIS Portal hypertension TIPS Splanchnic arterial vasodilation Reduced effective arterial blood volume Activation of vasoconstrictor /antinatriuretic systems Aldosterone antagonists Sympathetic nervous system Renin-aldosterone system Other diuretics Sodium retention Large-volume paracentesis + albumin ASCITES/EDEMA

  3. DIURETICS IN THE MANAGEMENT OF ASCITES Tips for clinical use • Treat the first episode of ascites with low doses of spironolactone. Don’t push weight loss above 0.5 Kg/day (1Kg/day in patients with leg edema) • 2. Full antagonism of aldosterone by spironolactone takes approx 5 days. Don’t expect immediate natriuresis • 3. Visit or call patients weekly when ascites is decreasing or the dose of diuretics has been increased. Educate patients on the effects of diuretics • 4. Monitor the effect of diuretics with body weight. Measure urine sodium in patients with poor or no response

  4. DIURETICS IN THE MANAGEMENT OF ASCITES Tips for clinical use 5. Use spironolactone with caution in patients with increased serum creatinine levels because of risk of hyperkalemia 6. Old patients or patients with chronic kidney disease have an impaired response to diuretics 7. Patients with pleural effusion respond poorly to diuretics and frequently develop side effects. Doses should be adjusted very carefully 8. USE DIURETICS WISELY. IMPORTANT SIDE EFFECTS CAUSED BY DIURETICS ARE VERY COMMON

  5. HYPOVOLEMIC HYPONATREMIA IN A PATIENT WITH CIRRHOSIS AND ASCITES DUE TO OVERDIURESIS 132 1.50 Furosemide (40 mg/day) + Spironolactone (200 mg/day) 130 1.25 128 Serum creatinine (mg/dL) ( ) Serum sodium (mEq/L) ( ) 1.00 126 0.75 124 Hepatic encephalopathy 122 0.50 1 2 3 4 5 6 7 8 9 10 11 Days BW (kg) 74 72 70.5 68.3 67.2 64.8 61.5 59.2 59.5 60.3 61.1

  6. Odds Ratio (CI) ALBUMIN IN LARGE-VOLUME PARACENTESIS Comparison albumin vs other expanders Effects on survival Bernardi et al, Hepatology 2012

  7. REFRACTORY ASCITES Pathogenesis and established therapies CIRRHOSIS Portal hypertension TIPS Intense splanchnic arterial vasodilation Severely reduced effective arterial blood volume Marked activation of vasoconstrictor /antinatriuretic systems Aldosterone antagonists Renin-aldosterone system Sympathetic nervous system Other diuretics Intense sodium retention Large-volume paracentesis + albumin REFRACTORY ASCITES

  8. Control of ascites Hepatorenal syndrome Hepatic encephalopathy Cost Survival Better with TIPS No difference Worse with TIPS - - No difference Better with TIPS? Better with TIPS - - Better with TIPS Less frequent with TIPS Worse with TIPS Greater with TIPS No difference Better with TIPS Worse with TIPS No difference - - Better with TIPS Less frequent with TIPS Worse with TIPS Better with TIPS - TIPS vs. PARACENTESIS FOR REFRACTORY ASCITESSummary of studies Lebrec et al., J Hepatol 1997 Rossle et al., N Engl J Med 2000 Ginès et al., Gastroenterology 2002 Sanyal et al., Gastroenterology 2003 Salerno et al., Hepatology 2005

  9. EASL GUIDELINES ON ASCITES IN CIRRHOSIS 2010 Management of Refractory Ascites - Repeated large volume paracentesis plus albumin (8 g/L of ascites removed) is the first line of treatment for refractory ascites - The use of TIPS should be considered in patients with very frequent requirement of paracentesis or in those in whom paracentesis is ineffective (e.g. due to the presence of loculated ascites) EASL Guidelines on Ascites, J Hepatol 2010

  10. HEPATORENAL SYNDROME Epstein et al., Am J Med 1970

  11. HEPATORENAL SYNDROME Clinical types Type 1 - Rapidly progressive renal failure: doubling of the initial serum creatinine concentration to a level greater than 2.5 mg/dL in less than 2 weeks -Clinical presentation::acute renal failure - Median survival: 2 weeks, if untreated Type 2 - Stable renal failure - Clinical presentation: refractory ascites - Median survival: 6 months International Ascites Club, Hepatology 1996

  12. TYPE 1 HEPATORENAL SYNDROME EASL Guidelines 2010 1. Consider liver transplantation; give priority to candidates 2. Terlipressin and albumin is the first-line treatment 3. Alternative therapies include norepinephrine and midodrine and octreotide plus albumin but information is limited 4. Consider TIPS if no response to vasoconstrictors in patients without contraindications (low applicability) 5. Use renal replacement therapy if no response to vasoconstrictors 6. Liver transplantation alone. No combined liver-kidney tx except for patients requiring prolonged renal support

  13. CIRCULATORY AND KIDNEY FUNCTION IN HEPATORENAL SYNDROME AND EFFECTS OF TERLIPRESSIN AND ALBUMIN CIRRHOSIS Portal hypertension Terlipressin Splanchnic arterial vasodilation Albumin Decreased effective arterial blood volume Vasoconstrictor systems Cerebral vasoconstriction Renal vasoconstriction Brachial/femoral vasoconstriction Maintenance of effective arterial blood volume HEPATORENAL SYNDROME

  14. CIRCULATORY AND KIDNEY FUNCTION IN HEPATORENAL SYNDROME AND EFFECTS OF TERLIPRESSIN AND ALBUMIN CIRRHOSIS Portal hypertension Splanchnic arterial vasoconstriction Increase in effective arterial blood volume Suppressed vasoconstrictor systems Cerebral Vasodilation?? Kidney vasodilation Brachial/femoral Vasodilation?? Maintenance of effective arterial blood volume IMPROVED KIDNEY FUNCTION

  15. HEPATORENAL SYNDROME Effects of terlipressin and albumin on circulatory and kidney function Pretreatment End of treatment p Serum creatinine (mg/dL) 3.9±0.7 1.5±0.2 <0.001 Serum sodium (mEq/L) 122±1 131±2 <0.01 Mean arterial pressure (mmHg) 68±2 80±4 <0.05 23±12 3±2 <0.01 Plasma renin activity (ng/mL.h) Plasma aldosterone (ng/dL) 342±73 89±29 <0.01 Plasma norepinephrine (pg/mL) 1,549±373 373±98 <0.01 Uriz et al., J Hepatol 2000

  16. PHARMACOLOGICAL TREATMENT OF TYPE-1 HEPATORENAL SYNDROME Changes in arterial pressure in respondersand non-responders Boyer T et al. JHepatol 2011

  17. SPECIFIC ISSUES IN THE MANAGEMENTOF PATIENTS WITH HEPATORENAL SYNDROME • Differential diagnosis between type-1 HRS and other causes of kidney failure • Evaluation and management of type-1 HRS associated with infections • Treatment of patients with type-2 HRS

  18. SPECIFIC ISSUES IN THE MANAGEMENTOF PATIENTS WITH HEPATORENAL SYNDROME • Differential diagnosis between type-1 HRS and other causes of kidney failure • Evaluation and management of type-1 HRS associated with infections • Treatment of patients with type-2 HRS

  19. 50 % 40 36% 30 25% 24% 20 15% 10 0 HEPATORENALSYNDROME PRE-RENALAKI INTRINSICAKI* OTHER CAUSES OF KIDNEY FAILURE IN CIRRHOSISProspective series of 265 hospitalized patients PRE-RENAL AKI: KIDNEY FAILURE DUE TO HYPOVOLEMIAINTRINSIC AKI: KIDNEY FAILURE DUE TO ACUTE TUBULAR NECROSISAKI, ACUTE KIDNEY INJURY Barreto et al., unpublished

  20. Constituent biomarkers NAG α-GST • N-acetylglucoseaminidase (NAG) • α-glutation-S-transferase (α-GST) • π-glutation-S-transferase (π-GST) KIM-1 MCP-1 π-GST β2-microglobuline Inducible biomarkers Low molecular weight proteins • β2-microglobuline BIOMARKERS FOR THE DIAGNOSIS OF ACUTE KIDNEY INJURY NGAL • Neutrophil gelatinase-associated • lipocalin (NGAL) • Kidney injury molecule-1 (KIM-1) • Monocyte chemoattractant • protein-1 (MCP-1) NGAL NGAL • Neutrophil gelatinase-associated • lipocalin (NGAL) NGAL

  21. 327 SENS 0.67SPECIF 0.86 URINE NGAL AND CAUSE OF KIDNEYFAILURE IN HOSPITALIZED CIRRHOTICS p<0.001 ∞ Median 32 33 67 98 417 * p<0.001** p<0.05∞ Miscellaneous: Chronic Kidney Disease, Nephrotoxicity … Barreto et al, unpublished

  22. SPECIFIC ISSUES IN THE MANAGEMENTOF PATIENTS WITH HEPATORENAL SYNDROME • Differential diagnosis between type-1 HRS and other causes of kidney failure • Evaluation and management of type-1 HRS associated with infections • Treatment of patients with type-2 HRS

  23. No Reversibility Age < 60 years Age ≥ 60 years % No Nosocomial infection Nosocomial infection TYPE-1 HEPATORENAL SYNDROME ASSOCIATED WITH SEPSIS Lack of reversibility with antibiotic therapy Barreto et al. Hepatology 2013

  24. a 0 Responders Non Responders Responders TYPE-1 HEPATORENAL SYNDROME ASSOCIATED WITH SEPSIS Effects of terlipressin and albumin Efficacy 65% Rodriguez E et al. unpublished

  25. SPECIFIC ISSUES IN THE MANAGEMENTOF PATIENTS WITH HEPATORENAL SYNDROME • Differential diagnosis between type-1 HRS and other causes of kidney failure • Evaluation and management of type-1 HRS associated with infections • Treatment of patients with type-2 HRS

  26. TREATMENT OF TYPE-2 HEPATORENAL SYNDROME • Information on treatment of type-2 HRS is limited • Terlipressin and albumin is effective in improving kidney function in approximately 60% of patients, but recurrence after treatment withdrawal is almost constant • The effect of pharmacological treatment on survival has not been evaluated in large studies • TIPS may improve renal function but an improvement in survival has not been demonstrated

  27. CONCLUSIONS • The use of kidney biomarkers, such as NGAL, may be useful in the differential diagnosis of HRS from other causes of acute kidney dysfunction, but more studies are needed before the use of biomarkers can be applied to clinical practice. • Terlipressin and albumin is the treatment of choice for type-1 HRS. Response to treatment is dependent on improvement of systemic hemodynamics. Early treatment may improve the response rate. • Type-1 HRS associated with sepsis is seldom reversible only with antibiotic treatment. Terlipressin and albumin appears effective in these patients

  28. BARCELONA LIVER CIRRHOSIS STUDY GROUP

More Related